Drug Profile
NN 1952
Alternative Names: NN1952Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merrion Pharmaceuticals; Novo Nordisk
- Developer Novo Nordisk
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus in Germany (PO)
- 11 Jun 2010 Novo Nordisk completes a phase I trial in Type 1 and Type 2 diabetes mellitus in Germany
- 07 Dec 2009 Phase-I clinical trials in Diabetes mellitus in Germany (PO)